The new and evolving pharmacotherapy of schizophrenia / Robin Emsley en Psychiatric Clinics of North America, Año 2003 - Vol. 26 No. 1 (Marzo)

Público ISBD [artículo]  inPsychiatric Clinics of North America > Año 2003 - Vol. 26 No. 1 (Marzo) . - pp. 141-163 Título : The new and evolving pharmacotherapy of schizophrenia Tipo de documento: texto impreso Autores: Robin Emsley, Autor ; Piet Oosthuizen, Autor Fecha de publicación: 2020 Artículo en la página: pp. 141-163 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Calidad de vida, Esquizofrenia. Resumen: Based on the evidence presented here, the following tentative conclusions can be drawn. Atypical antipsychotics (except amisulpride) have shown superiority over placebo in acute schizophrenia. Compared with conventional antipsychotics, they are at least as effective. Generally, analyses employing conservative criteria (e.g., Cochrane reviews) report few efficacy differences between atypical and conventional agents. Link: ./index.php?lvl=notice_display&id=24826 [artículo] The new and evolving pharmacotherapy of schizophrenia [texto impreso] / Robin Emsley, Autor ; Piet Oosthuizen, Autor . - 2020 . - pp. 141-163. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Psychiatric Clinics of North America > Año 2003 - Vol. 26 No. 1 (Marzo) . - pp. 141-163 Palabras clave: Antipsicóticos, Calidad de vida, Esquizofrenia. Resumen: Based on the evidence presented here, the following tentative conclusions can be drawn. Atypical antipsychotics (except amisulpride) have shown superiority over placebo in acute schizophrenia. Compared with conventional antipsychotics, they are at least as effective. Generally, analyses employing conservative criteria (e.g., Cochrane reviews) report few efficacy differences between atypical and conventional agents. Link: ./index.php?lvl=notice_display&id=24826

---

1 (1 - 1 / 1)